Ovid Therapeutics Inc. is taking strides in the development of vital medications for patients and families dealing with epilepsies and seizure-related neurological disorders across the United States. Currently, the biopharmaceutical company is closely tracking Phase 3 clinical trials on soticlestat, a novel cholesterol 24 hydroxylase inhibitor, that has the potential to treat patients suffering from resistant epilepsies. Additionally, Ovid Therapeutics is looking into other viable options, such as OV329, a GABA aminotransferase inhibitor in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV350, a small molecule direct activator of the KCC2 transporter, is also in Phase 1 clinical trials for treating epilepsies. At the preclinical stage, Ovid Therapeutics remains focused on the development of OV815, which targets KIF1A-associated neurological disorder (KAND). OV825 has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome). OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome, is also being looked at closely. The company cultivates license and collaboration agreements with a range of credible companies, including Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. Ovid Therapeutics was brought to life in 2014 and is based out of New York City.
Ovid Therapeutics Inc.'s ticker is OVID
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at Ovid Therapeutics Inc.
It is https://ovidrx.com/
Ovid Therapeutics Inc. is in the Healthcare sector
Ovid Therapeutics Inc. is in the Biotechnology industry
The following five companies are Ovid Therapeutics Inc.'s industry peers: